Werewolf Therapeutics, Inc.

NasdaqGS:HOWL

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 55.64 M

Share Price

USD 1.24

Avg Daily Volume

393,277

Change (1 day)

2.48%

Change (1 year)

-57.09%

Change (YTD)

-16.22%

Werewolf Therapeutics, Inc. Share Price Year-To-Date (YTD) return on June 18, 2025: -16.22%

Werewolf Therapeutics, Inc. Share Price Year-To-Date (YTD) return is -16.22% on June 18, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Werewolf Therapeutics, Inc. 52-week low Share Price is USD 3.63 on June 18, 2025, which is 192.74% above the current Share Price.
Werewolf Therapeutics, Inc. 52-week low Share Price is USD 0.63 on June 18, 2025, which is -49.19% below the current Share Price.
Werewolf Therapeutics, Inc. average Share Price for the last 52 weeks is USD 1.71.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGS: HOWL

Werewolf Therapeutics, Inc.

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue
Employees	46
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.